Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MREO |
---|---|---|
09:32 ET | 10067 | 3.8 |
09:33 ET | 300 | 3.795 |
09:35 ET | 1200 | 3.77 |
09:37 ET | 7755 | 3.75 |
09:39 ET | 14270 | 3.74 |
09:42 ET | 48105 | 3.705 |
09:44 ET | 60916 | 3.67 |
09:46 ET | 37324 | 3.6299 |
09:48 ET | 24236 | 3.64 |
09:50 ET | 4712 | 3.66 |
09:51 ET | 11311 | 3.645 |
09:53 ET | 13554 | 3.63 |
09:55 ET | 5347 | 3.63 |
09:57 ET | 9394 | 3.655 |
10:00 ET | 15404 | 3.665 |
10:02 ET | 4652 | 3.66 |
10:04 ET | 10237 | 3.67 |
10:06 ET | 4906 | 3.68 |
10:08 ET | 500 | 3.6731 |
10:09 ET | 44667 | 3.65 |
10:11 ET | 10782 | 3.67 |
10:13 ET | 19378 | 3.655 |
10:15 ET | 30029 | 3.655 |
10:18 ET | 45111 | 3.653 |
10:20 ET | 6762 | 3.635 |
10:22 ET | 9000 | 3.625 |
10:24 ET | 5538 | 3.625 |
10:26 ET | 35586 | 3.665 |
10:27 ET | 21059 | 3.665 |
10:29 ET | 2600 | 3.66 |
10:31 ET | 5191 | 3.655 |
10:33 ET | 8821 | 3.64 |
10:36 ET | 87942 | 3.65 |
10:38 ET | 26306 | 3.65 |
10:40 ET | 26251 | 3.645 |
10:42 ET | 3216 | 3.6497 |
10:44 ET | 8568 | 3.6484 |
10:45 ET | 34408 | 3.65 |
10:47 ET | 13340 | 3.665 |
10:49 ET | 11594 | 3.655 |
10:51 ET | 6316 | 3.6499 |
10:54 ET | 9910 | 3.625 |
10:56 ET | 16980 | 3.605 |
10:58 ET | 3978 | 3.605 |
11:00 ET | 23609 | 3.605 |
11:02 ET | 20590 | 3.595 |
11:03 ET | 3917 | 3.6 |
11:05 ET | 4643 | 3.585 |
11:07 ET | 8401 | 3.6052 |
11:09 ET | 3800 | 3.6 |
11:12 ET | 1200 | 3.6 |
11:14 ET | 518 | 3.595 |
11:16 ET | 21295 | 3.6 |
11:18 ET | 14413 | 3.615 |
11:20 ET | 13550 | 3.605 |
11:21 ET | 9677 | 3.605 |
11:23 ET | 16736 | 3.6193 |
11:25 ET | 20042 | 3.6194 |
11:27 ET | 9900 | 3.6299 |
11:30 ET | 7351 | 3.64 |
11:32 ET | 8507 | 3.625 |
11:34 ET | 4643 | 3.645 |
11:36 ET | 1000 | 3.64 |
11:38 ET | 5968 | 3.63 |
11:39 ET | 4279 | 3.62 |
11:41 ET | 12383 | 3.61 |
11:43 ET | 2500 | 3.6091 |
11:45 ET | 2700 | 3.605 |
11:48 ET | 2945 | 3.6193 |
11:50 ET | 16036 | 3.605 |
11:52 ET | 13466 | 3.605 |
11:54 ET | 9150 | 3.605 |
11:56 ET | 500 | 3.605 |
11:57 ET | 1100 | 3.605 |
11:59 ET | 974 | 3.605 |
12:01 ET | 6636 | 3.605 |
12:03 ET | 16285 | 3.605 |
12:06 ET | 3775 | 3.6115 |
12:08 ET | 2600 | 3.605 |
12:10 ET | 1166 | 3.6011 |
12:12 ET | 1100 | 3.61 |
12:14 ET | 12015 | 3.605 |
12:15 ET | 759 | 3.61 |
12:17 ET | 1100 | 3.6 |
12:19 ET | 1110 | 3.61 |
12:21 ET | 2512 | 3.6 |
12:24 ET | 2800 | 3.6075 |
12:26 ET | 9948 | 3.5809 |
12:28 ET | 15616 | 3.595 |
12:30 ET | 1909 | 3.595 |
12:32 ET | 32618 | 3.595 |
12:33 ET | 27939 | 3.595 |
12:35 ET | 3000 | 3.595 |
12:37 ET | 600 | 3.59 |
12:39 ET | 3232 | 3.61 |
12:42 ET | 4282 | 3.6049 |
12:44 ET | 400 | 3.6 |
12:46 ET | 1364 | 3.61 |
12:48 ET | 5883 | 3.605 |
12:50 ET | 1400 | 3.605 |
12:51 ET | 3500 | 3.6 |
12:53 ET | 17674 | 3.6 |
12:55 ET | 363 | 3.595 |
12:57 ET | 1600 | 3.5973 |
01:00 ET | 863 | 3.595 |
01:02 ET | 200 | 3.59 |
01:04 ET | 990 | 3.5977 |
01:06 ET | 3000 | 3.5999 |
01:08 ET | 800 | 3.595 |
01:09 ET | 2196 | 3.59 |
01:11 ET | 2776 | 3.595 |
01:13 ET | 1477 | 3.6 |
01:15 ET | 2027 | 3.595 |
01:18 ET | 4622 | 3.595 |
01:20 ET | 1592 | 3.59 |
01:22 ET | 1926 | 3.585 |
01:24 ET | 3513 | 3.585 |
01:26 ET | 1090 | 3.585 |
01:27 ET | 35789 | 3.575 |
01:29 ET | 3375 | 3.575 |
01:31 ET | 3393 | 3.565 |
01:33 ET | 22703 | 3.56 |
01:36 ET | 1230 | 3.565 |
01:38 ET | 18170 | 3.58 |
01:40 ET | 4348 | 3.595 |
01:42 ET | 200 | 3.595 |
01:44 ET | 2745 | 3.595 |
01:45 ET | 1159 | 3.6 |
01:47 ET | 11580 | 3.59 |
01:49 ET | 2188 | 3.57 |
01:51 ET | 5252 | 3.585 |
01:54 ET | 100 | 3.585 |
01:56 ET | 1449 | 3.585 |
01:58 ET | 1813 | 3.59 |
02:00 ET | 700 | 3.59 |
02:02 ET | 3485 | 3.585 |
02:03 ET | 991 | 3.58 |
02:05 ET | 6500 | 3.58 |
02:07 ET | 2043 | 3.575 |
02:09 ET | 5000 | 3.585 |
02:12 ET | 3200 | 3.585 |
02:14 ET | 1600 | 3.585 |
02:16 ET | 5709 | 3.575 |
02:18 ET | 1000 | 3.5701 |
02:20 ET | 3671 | 3.565 |
02:21 ET | 4549 | 3.57 |
02:23 ET | 2553 | 3.56 |
02:25 ET | 4119 | 3.545 |
02:27 ET | 16586 | 3.555 |
02:30 ET | 600 | 3.555 |
02:32 ET | 2310 | 3.555 |
02:34 ET | 1375 | 3.56 |
02:36 ET | 5403 | 3.555 |
02:38 ET | 3379 | 3.545 |
02:39 ET | 24247 | 3.565 |
02:41 ET | 14685 | 3.585 |
02:43 ET | 4985 | 3.585 |
02:45 ET | 100 | 3.59 |
03:15 ET | 21147 | 3.545 |
03:17 ET | 5314 | 3.535 |
03:19 ET | 2279 | 3.53 |
03:21 ET | 4095 | 3.535 |
03:24 ET | 2378 | 3.53 |
03:26 ET | 10926 | 3.525 |
03:28 ET | 11170 | 3.525 |
03:30 ET | 12107 | 3.5308 |
03:32 ET | 5209 | 3.525 |
03:33 ET | 24815 | 3.525 |
03:35 ET | 8590 | 3.525 |
03:37 ET | 14093 | 3.525 |
03:39 ET | 8580 | 3.52 |
03:42 ET | 12395 | 3.525 |
03:44 ET | 9744 | 3.525 |
03:46 ET | 6603 | 3.52 |
03:48 ET | 18412 | 3.521 |
03:50 ET | 24696 | 3.505 |
03:51 ET | 18762 | 3.515 |
03:53 ET | 16951 | 3.5125 |
03:55 ET | 39578 | 3.535 |
03:57 ET | 12426 | 3.532 |
04:00 ET | 114049 | 3.53 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Mereo BioPharma Group PLC | 543.1M | -13.3x | --- |
Kezar Life Sciences Inc | 544.3M | -0.6x | --- |
SS Innovations International Inc | 512.2M | -21.5x | --- |
Altimmune Inc | 540.8M | -4.9x | --- |
Perspective Therapeutics Inc | 531.3M | -6.4x | --- |
PureTech Health PLC | 520.3M | -7.6x | --- |
Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development. Etigilimab is an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity. Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late line ovarian cancer.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $543.1M |
---|---|
Revenue (TTM) | $1.2M |
Shares Outstanding | 153.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.98 |
EPS | $-0.26 |
Book Value | $0.36 |
P/E Ratio | -13.3x |
Price/Sales (TTM) | 448.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,918.95% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.